Scientists hunt for immune clues to predict breast cancer treatment response
NCT ID NCT07407244
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is collecting tumor and blood samples from 268 women with early breast cancer before they receive standard chemotherapy. Researchers want to see if certain immune-related factors in the tumor and circulating tumor DNA can predict whether the cancer will completely disappear after treatment. The goal is to better understand who benefits most from chemotherapy, but no new drug is being tested.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors identify which breast cancer patients are most likely to benefit from chemotherapy before surgery.
- What could go wrong
- This is an observational study, not a treatment trial. It may not lead to immediate changes in care, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Oncology Ljubljana
Ljubljana, 1000, Slovenia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?